Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Wyeth Low-Dose Prempro Approval Offers Message To Offset Safety Issues

Mar 17 2003

• By The Pink Sheet

Related Content

Prempro Cancer Risk Addressed In 550,000 Physician Letters, Label Review

Jul 15 2002

FDA Hormone Therapy Outreach Will Stress Short-Term, Low-Dose Use

Mar 10 2003

Wyeth Estrogens GMP Surveillance Will Address Dissolution Issues

Mar 17 2003

Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March

Jan 13 2003

FDA Hormone Therapy Risk Management Options Include Narrower Indication

Oct 28 2002

Wyeth Low-Dose PremPro Osteoporosis sNDA Filing Planned For June

May 21 2001

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window